 |
|
|
| |
Multi-Biomarker Validation of MRI-PDFF- and MRE-Derived Treatment Response with BMS-986036 (PEG-FGF21):
A Secondary Analysis of a Multi-Center Clinical Trial in Non-Alcoholic Steatohepatitis (NASH)
|
| |
| |
AASLD: BMS-986036 (PEGylated FGF21) in Patients with Non-Alcoholic Steatohepatitis: A Phase 2 Study - (10/26/17)
Reported by Jules Levin
American Association for the Study of Liver Diseases (AASLD 2017), Washington, DC, October 20-24, 2017
Rohit Loomba,1 Edgar D. Charles,2 Arun Sanyal,3 John Vierling,4 Yuping Dong,2 Robert Gagnon,2 Yi Luo,2 Shuyan Du,2 Rose Christian2
1University of California-San Diego, San Diego, CA, USA; 2Bristol-Myers Squibb, Lawrenceville, NJ, USA; 3Virginia Commonwealth University, Richmond, VA, USA; 4Baylor College of Medicine, Houston, TX, USA
|
| |
|
|
|
|
|
